Patents by Inventor Stefan Senger

Stefan Senger has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • N-pyrazolyl carboxamides as CRAC channel inhibitors
    Patent number: 8399436
    Abstract: The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: March 19, 2013
    Assignee: Glaxo Group Limited
    Inventors: David George Allen, Diane Mary Coe, Anthony William James Cooper, Paul Martin Gore, David House, Stefan Senger, Steven Leslie Sollis, Sadie Vile, Caroline Wilson
  • N-PYRAZOLYL CARBOXAMIDES AS CRAC CHANNEL INIHIBITORS
    Publication number: 20120053150
    Abstract: The present invention relates to amide compounds, processes for their preparation, pharmaceutical compositions containing these compounds and to their use in the treatment of disorders, conditions or disorders such as allergic disorders, inflammatory disorders and disorders of the immune system.
    Type: Application
    Filed: April 22, 2010
    Publication date: March 1, 2012
    Inventors: David George Allen, Diane Mary Coe, Anthony William James Cooper, Paul Martin Gore, David House, Stefan Senger, Steven Leslie Sollis, Sadie Vile, Caroline Wilson
  • PYRAZOLE AND TRIAZOLE CARBOXAMIDES AS CRAC CHANN EL INHIBITORS
    Publication number: 20120035237
    Abstract: The present invention relates to amide compounds, processes for their preparation, intermediates usable in these processes, pharmaceutical compositions containing these compounds and to their use in therapy.
    Type: Application
    Filed: April 22, 2010
    Publication date: February 9, 2012
    Inventors: Diane Mary Coe, Anthony William James Cooper, Paul Martin Gore, David House, Stefan Senger, Sadie Vile
  • Receptor antagonists and their methods of use
    Patent number: 8048907
    Abstract: The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: November 1, 2011
    Assignee: Glaxo Group Limited
    Inventors: Laura J Chambers, Robert Gleave, Stefan Senger, Daryl Simon Walter
  • Novel Receptor Antagonists and Their Methods of Use
    Publication number: 20100144829
    Abstract: The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
    Type: Application
    Filed: February 18, 2010
    Publication date: June 10, 2010
    Inventors: Laura J. Chambers, Robert Gleave, Stefan Senger, Daryl Simon Walter
  • Pyrrolidine derivatives as factor Xa inhibitors
    Patent number: 7517879
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: April 14, 2009
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • 1-Benzazepine-3-Sulfonylamino-2-Pyrroridones as Factor Xa Inhibitors
    Publication number: 20080306045
    Abstract: The invention relates to chemical entities of formula (I): and/or pharmaceutically acceptable derivative(s) thereof. The invention also relates to processes for the preparation of compounds of formula (I), pharmaceutical compositions containing compounds of formula (I) and to the use of compounds of formula (I) in medicine, particularly in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: November 22, 2006
    Publication date: December 11, 2008
    Inventors: Laure Camus, Reshma Chudasama, Caroline Jane Day, Deepali Deshmukh, John Gerald Gleason, John David Harling, Chao-Pin Lee, Paula Saklatvala, Stefan Senger, Sarah Vallance, John Watson, Nigel Stephen Watson, Robert John Young, Barbara Yuan
  • Pyrrolidine derivatives as factor Xa inhibitors
    Patent number: 7429587
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: September 30, 2008
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Pyrrolidine derivatives as factor XA inhibitors
    Patent number: 7326785
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: October 11, 2006
    Date of Patent: February 5, 2008
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Novel Receptor Antagonists and Their Methods of Use
    Publication number: 20080009541
    Abstract: The present invention relates to novel oxo-prolinamide derivatives of formula (I) which modulate P2X7 receptor function and are capable of antagonizing the effects of ATP at the P2X7 receptor and the use of such compounds or pharmaceutical compositions thereof in the treatment of disorders mediated by the P2X7 receptor, for example pain, inflammation and neurodegeneration.
    Type: Application
    Filed: July 3, 2007
    Publication date: January 10, 2008
    Applicant: GLAXO GROUP LIMITED
    Inventors: Laura Chambers, Robert Gleave, Stefan Senger, Daryl Walter
  • Pyrrolidin-2-one derivatives as inhibitors of factor xa
    Patent number: 7282497
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: October 16, 2007
    Assignee: Glaxo Group Limited
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • 2-Pyrrolidone Derivatives And Use Thereof As Factor Xa Inhibitors
    Publication number: 20070203206
    Abstract: A compound of formula (I) and pharmaceutically acceptable salts, solvates and hydrolysable esters thereof.
    Type: Application
    Filed: July 17, 2004
    Publication date: August 30, 2007
    Inventors: Alan Borthwick, Savvas Kleanthous, Stefan Senger, Ian Smith
  • PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS
    Publication number: 20070155745
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: October 11, 2006
    Publication date: July 5, 2007
    Inventors: Chuen Chan, Julie Hamblin, Henry Kelly, Nigel King, Andrew Mason, Vipulkumar Patel, Stefan Senger, Gita Shah, Nigel Watson, Helen Weston, Caroline Whitworth, Robert Young
  • PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS
    Publication number: 20070142375
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: October 11, 2006
    Publication date: June 21, 2007
    Inventors: Chuen CHAN, Julie Hamblin, Henry Kelly, Nigel King, Andrew Mason, Vipulkumar Patel, Stefan Senger, Gita Shah, Nigel Watson, Helen Weston, Caroline Whitworth, Robert Young
  • PYRROLIDINE DERIVATIVES AS FACTOR XA INHIBITORS
    Publication number: 20070142374
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Application
    Filed: October 11, 2006
    Publication date: June 21, 2007
    Inventors: Chuen CHAN, Julie Hamblin, Henry Kelly, Nigel King, Andrew Mason, Vipulkumar Patel, Stefan Senger, Gita Shah, Nigel Watson, Helen Weston, Carolin Whitworth, Robert Young
  • Pyrrolidin-2-one derivatives as inhibitors of factor xa
    Patent number: 7226929
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: March 17, 2006
    Date of Patent: June 5, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Pyrrolidine derivatives as Factor Xa inhibitors
    Patent number: 7186717
    Abstract: The invention relates to compounds of formula (I) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: March 6, 2007
    Assignee: SmithKline Beecham Corporation
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • 2-(3-sulfonylamino-2-oxopyrrolidin-1-yl)propanamides as factor xa inhibitors
    Patent number: 7179835
    Abstract: The invention relates to compounds of formula (I) pharmaceutical compositions containing the same as well as methods of treating patients suffering from a condition susceptible to amelioration by a Factor Xa inhibitor using the same.
    Type: Grant
    Filed: November 13, 2002
    Date of Patent: February 20, 2007
    Assignee: Glaxo Group Limited
    Inventors: Alan David Borthwick, Matthew Campbell, Chuen Chan, Henry Anderson Kelly, Nigel Paul King, Savvas Kleanthous, Andrew McMurtrie Mason, Stefan Senger, Paul William Smith, Nigel Stephen Watson, Robert John Young
  • Pyrrolidin-2-one derivatives as inhibitors of factor Xa
    Patent number: 7084139
    Abstract: The invention relates to compounds of formula (Ic) processes for their preparation, pharmaceutical compositions containing them and to their use in medicine, particularly use in the amelioration of a clinical condition for which a Factor Xa inhibitor is indicated.
    Type: Grant
    Filed: June 6, 2002
    Date of Patent: August 1, 2006
    Assignee: SmithKline Beecham Corporation
    Inventors: Chuen Chan, Julie Nicole Hamblin, Henry Anderson Kelly, Nigel Paul King, Andrew McMurtrie Mason, Vipulkumar Kantibhai Patel, Stefan Senger, Gita Punjabhai Shah, Nigel Stephen Watson, Helen Elisabeth Weston, Caroline Whitworth, Robert John Young
  • Pyrrolydin-2-one derivatives as inhibitors of thrombin and factor xa
    Publication number: 20060166985
    Abstract: The invention relates to novel chemical compounds, pharmaceutically acceptable derivatives thereof, processes for their preparation, pharmaceutical compositions containing them, and to their use in medicine, particularly use in the amelioration of a clinical condition for which a thrombin inhibitor is indicated.
    Type: Application
    Filed: December 4, 2003
    Publication date: July 27, 2006
    Inventors: Alan Borthwick, Chuen Chan, Henry Kelly, Simon Peace, Stefan Senger, Gita Shah, Stefan Smith, Steven Smith, Nigel Watson, Robert West, Robert Young